| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:30315952 | IVR | 12 mg/kg | 12 mg/kg | Affects testis development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 12 mg/kg | 12 mg/kg | Affects sertoli cells function | Reproductive endocrine-mediated perturbations | |
| IVR | 12 mg/kg | 12 mg/kg | Decreased testosterone levels in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 3 mg/kg | 3 mg/kg | Increased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 3 mg/kg | 3 mg/kg | Affects testis development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 12 mg/kg | 12 mg/kg | Affects leydig cells function | Reproductive endocrine-mediated perturbations | |
| IVR | 6 mg/kg | 6 mg/kg | Affects testis development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:33423197 | IVR | 1 mg/kg | 1 mg/kg | Changes in morphology of thyroid gland | Metabolic endocrine-mediated perturbations |
| IVR | 1 mg/kg | 1 mg/kg | Induce apoptosis in thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Oxidative stress in thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Decrease in T3 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Increased weights of thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Decreased body weights | Metabolic endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Increase in TSH levels | Metabolic endocrine-mediated perturbations | |
| PMID:36860759 | IVR | 1.5 mg/kg | 1.5 mg/kg | Oxidative stress in testis | Reproductive endocrine-mediated perturbations |
| IVR | 1.5 mg/kg | 1.5 mg/kg | Decreased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 1.5 mg/kg | 1.5 mg/kg | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 1.5 mg/kg | 1.5 mg/kg | Decreased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 1.5 mg/kg | 1.5 mg/kg | Changes in testicular morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 1.5 mg/kg | 1.5 mg/kg | Atrophy in seminiferous tubules | Reproductive endocrine-mediated perturbations | |
| IVR | 1.5 mg/kg | 1.5 mg/kg | Affects spermatogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 1.5 mg/kg | 1.5 mg/kg | Abnormal sperm morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 1.5 mg/kg | 1.5 mg/kg | Changes in morphology of seminiferous tubules | Reproductive endocrine-mediated perturbations | |
| IVR | 1.5 mg/kg | 1.5 mg/kg | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| PMID:37931768 | IVR | 25 ppm | 25 ppm | Changes in ovarian morphology | Reproductive endocrine-mediated perturbations |
| IVR | 25 ppm | 25 ppm | Epigenomic alterations in ovary | Reproductive endocrine-mediated perturbations | |
| IVR | 25 ppm | 25 ppm | Induce apoptosis of ovarian follicles | Reproductive endocrine-mediated perturbations | |
| IVR | 25 ppm | 25 ppm | Affects ovarian follicles population | Reproductive endocrine-mediated perturbations | |
| PMID:38532648 | IVR | 1 - 5 ppm | 1 - 5 ppm | Affects expression of estrogen receptor-beta (ER-beta) | Reproductive endocrine-mediated perturbations |
| IVR | 1 - 5 ppm | 1 - 5 ppm | Increased hypothalamus weights | Neurological endocrine-mediated perturbations | |
| IVR | 1 - 5 ppm | 1 - 5 ppm | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations | |
| IVR | 1 - 5 ppm | 1 - 5 ppm | Decreased body weights | Metabolic endocrine-mediated perturbations | |
| IVR | 1 - 5 ppm | 1 - 5 ppm | Increased weights of pituitary gland | Neurological endocrine-mediated perturbations | |
| IVR | 1 - 5 ppm | 1 - 5 ppm | Decreased weights of pituitary gland | Neurological endocrine-mediated perturbations | |
| IVR | 1 - 5 ppm | 1 - 5 ppm | Affects pituitary gland function | Metabolic endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| PMID:39711520 | IVR | 5 ppm | 5 ppm | Decreased mitochondrial membrane potential in ovarian cells | Reproductive endocrine-mediated perturbations |
| IVR | 5 ppm | 5 ppm | Induce apoptosis of ovarian follicles | Reproductive endocrine-mediated perturbations | |
| IVR | 5 ppm | 5 ppm | Oxidative stress in ovaries | Reproductive endocrine-mediated perturbations | |
| IVR | 5 ppm | 5 ppm | Abnormal oocyte morphology | Reproductive endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.